Value of infliximab (Remicade (R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group
| Autor: | Geert Ossenkoppele, Antoine Thyss, Petra Muus, H. Zwierzina, C. Denzlinger, Theo de Witte, Karel Indrak, Dominik Selleslag, Frédéric Baron, Michel Delforge, Sergio Amadori, Stefan Suciu |
|---|---|
| Přispěvatelé: | Hematology, CCA - Innovative therapy |
| Rok vydání: | 2012 |
| Předmět: |
Male
medicine.medical_specialty Phases of clinical research Antineoplastic Agents Lower risk Gastroenterology law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Translational research [ONCOL 3] Internal medicine medicine Clinical endpoint Humans Acute leukemia business.industry Myelodysplastic syndromes Translational research Immune Regulation [ONCOL 3] Antibodies Monoclonal Hematology medicine.disease Infliximab 3. Good health Surgery 030220 oncology & carcinogenesis Rheumatoid arthritis Myelodysplastic Syndromes Female Original Articles and Brief Reports business Settore MED/15 - Malattie del Sangue 030215 immunology medicine.drug |
| Zdroj: | Haematologica, 97(4), 529-533. Ferrata Storti Foundation Haematologica, 97, 4, pp. 529-33 Haematologica, 97, 529-33 Baron, F, Suciu, S, Amadori, S, Muus, P, Zwierzina, H, Denzlinger, C, Delforge, M, Thyss, A, Selleslag, D, Indrak, K, Ossenkoppele, G J & de Witte, T M 2012, ' Value of infliximab (Remicade (R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group ', Haematologica, vol. 97, no. 4, pp. 529-533 . https://doi.org/10.3324/haematol.2011.044347 |
| ISSN: | 0390-6078 |
| DOI: | 10.3324/haematol.2011.044347 |
| Popis: | Contains fulltext : 110161.pdf (Publisher’s version ) (Open Access) Tumor-necrosis factor alpha activity has been correlated to ineffective erythropoiesis in lower risk myelodysplastic syndromes. Infliximab (Remicade((R))) is an anti-tumor necrosis factor alpha chimeric antibody that is used in the treatment of patients with rheumatoid arthritis or Crohn's disease. Forty-six patients with myelodysplastic syndromes and a relatively low risk of developing acute leukemia were included in a randomized phase II study assessing the therapeutic activity of two dosages of infliximab administration (3 mg/kg vs. 5 mg/kg). The primary end point was the response rate. Responses were observed in 3 of 22 patients (13.1%) randomized to the 3 mg/kg arm, versus 0 of 21 patients randomized in the 5 mg/kg arm. According to the statistical design of the current study, neither of the two infliximab dose schedules tested showed sufficient activity as a single agent in this cohort of unselected patients with early myelodysplastic syndrome. 01 april 2012 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|